Bayer continued its leadership shuffle not only at its world headquarters in Germany but at two U.S.–based subsidiaries. Yet most of the executive movement of late has been at smaller companies.
At this week’s American Academy of Neurology annual meeting, Amylyx provided additional data from its Phase III amyotrophic lateral sclerosis study showing the full extent of Relyvrio’s failure.
The trial results add to a growing body of clinical evidence that suggests GLP-1 drugs, which include popular treatments such as Lilly’s Mounjaro and Novo Nordisk’s Wegovy, have medical benefits beyond diabetes and weight loss.
Sage Therapeutics said it will stop development of its experimental drug to treat Parkinson’s disease after the treatment failed a mid-stage study, sending the company’s shares tumbling 36% before the bell.
Today the drugmaker said long-term data showed that its blockbuster shingles vaccine, Shingrix, had 79.7% efficacy in participants aged 50 years and above, six to 11 years after vaccination.
Pharmacy benefit managers (PBMs) are in the crosshairs of Republicans and Democrats in Congress but have so far dodged any new litigation or reforms that had been targeted for inclusion in last month’s U.S. government budget deal.
